Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese
× To share and enhance best practice management of CML, experts and interested clinicians can discuss difficult or interesting CML cases here. Physicians submit a brief history of the patient and the case for discussion (no more than 200 words) by posting it in this forum ("New Discussion" button below). Please include the country of origin.

Each clinical case will be forwarded to the expert clinical panel for a brief independent response. Consideration should be given to patient confidentiality. Details that are not critical to the case can be changed to preserve anonymity. Please consider including your email with the case. This will not be posted on the website, but is useful should further details be requested by the moderator.

As a full clinical history is necessary for accurate comment, cases and comments on the Forum are ONLY ACCEPTED FROM PHYSICIANS. If individual patients have a specific question we encourage them to contact their healthcare provider. General questions can be emailed to info@cml-foundation.org.

DISCLAIMER: The iCMLf does not recommend or endorse any specific tests, physicians, products, procedures, or opinions, and disclaims any representation, warranty, or guaranty as to the same. Reliance on any information provided in this Forum is solely at your own risk.

imatinib and cardiomyopathy

More
13 years 3 months ago #46 by terang3
imatinib and cardiomyopathy was created by terang3
would be interested in your opinion about the following case:

I have a patient, aged 54, with mild cardiomyopathy (fall in EF from 56% in 2006 to 45-50%, recent SVT and unremarkable coronary a’s) who has been on Glivec for 9 years (since 2001) and in molecular remission for most of the last 6 years. The patient has only had one positive molecular test in that time . This occurred in late 2008.

For other reasons (long-term skin issues) I had been contemplating cessation of Glivec and close molecular monitoring.

Would you stop the treatment and observe with freq. molecular monitoring

Many thanks for your consideration.
Quick Reply

Reply to terang3

Your e-mail address will only be available to administators.
Go to editor..
Note: BBcode and smileys are still usable.
  • Michele Baccarani
  • Michele Baccarani's Avatar
13 years 2 months ago #47 by Michele Baccarani
Replied by Michele Baccarani on topic Re:imatinib and cardiomyopathy
YES, I’d discontinue ther treatment, monitoring the BCR-ABL transcripts level monthly for 6 months, then every three months for another 12 months, then every 6 months, recommending to use peripheral blood, and to sample 20 ml of blood for each test.

Thank you, best regards, Michele Baccarani
Quick Reply

Reply to Michele Baccarani

Your e-mail address will only be available to administators.
Go to editor..
Note: BBcode and smileys are still usable.
More
13 years 2 months ago #48 by tim
Replied by tim on topic Re:imatinib and cardiomyopathy
Hi Kerry,

I think the link between imaitnib and cardiac dysfunction is not so convincing given the large scale case reviews conducted over the past few years so I am not sure the deterioration is likely to be due to imatinib, but I agree it is possible. I presume he has been in complete molecular response for several years rather than MMR. If so you do have the option of stopping with very close PCR monitoring. Unfortunately only about 40% can stop and remain in CMR but you probably don't lose anything by trying. If he had a high Sokal score at diagnosis his chances of remaining in CMR off-therapy seem to be quite low based on the French study (recent Lancet Oncology paper) so his Sokal score may influence your decision.

The other consideration is switching to another TKI but if cardiac dysfunction is driven by ABL blockade this might actually lead to greater dysfunction. I am not sure there have been any animal studies or long term clinical studies to look at this question.

Regards
Tim
Quick Reply

Reply to tim

Your e-mail address will only be available to administators.
Go to editor..
Note: BBcode and smileys are still usable.
More
13 years 2 months ago #50 by serenamerante
Replied by serenamerante on topic Re:imatinib and cardiomyopathy
I agree with Michele Baccarani and Tim. After a long period as the patient got it is feasible to stop Imatinib starting a close molecular monitoring as FISH as: anyway in may experience if the patient relapses, after such his long story, the response to imatinib will be prompt.
Best wishes
Quick Reply

Reply to serenamerante

Your e-mail address will only be available to administators.
Go to editor..
Note: BBcode and smileys are still usable.
  • Pankaj Malhotra
  • Pankaj Malhotra's Avatar
13 years 2 months ago #57 by Pankaj Malhotra
Replied by Pankaj Malhotra on topic Re:imatinib and cardiomyopathy
I would like to ask a few questions here:

1. Do we have baseline cardiac evaluation of the patient prior to start of Imatinib mesylate?

2. Why was the evaluation of cardiac functions done in 2006?

3. What are the other risk factors for cardiac dysfunction (e.g. Obesity, Abnormal lipids, Smoking etc.)

4. How was coronaries evaluated (by angiography or any other method)

5. What is cardiologist opinion regarding decrease in ejection fraction (is there any other explanation)?

6. Is decrease in cardiac ejection fraction documented by Echocardiography or by MUGA scan?

7. Unless a clear link is establised between Imatinib mesylate and ongoing cardiac dysfunction, stopping imatinib mesylate is experimetal and should be done with clear discussion with patient.

8. Since we are talking of experimental approaches, what is the role of maintenance IFN after stopping IFN?
(Burchert A et al. Sustained Molecular Response With Interferon Alfa Maintenance After Induction Therapy With Imatinib Plus Interferon Alfa in Patients With Chronic Myeloid Leukemia. JCO 2010; 28:1429-35)

Thanks and kind regards
Quick Reply

Reply to Pankaj Malhotra

Your e-mail address will only be available to administators.
Go to editor..
Note: BBcode and smileys are still usable.
Moderators: Nicola, arlene